CTXR - Citius Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.4400
-0.0200 (-1.37%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.4600
Open1.4900
Bid1.4200 x 800
Ask1.5000 x 800
Day's Range1.4100 - 1.4990
52 Week Range0.8580 - 3.2500
Volume119,422
Avg. Volume159,125
Market Cap26.669M
Beta (3Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-1.0110
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • ACCESSWIRE8 days ago

    LD Micro Virtual Conference Is Live, March 12th and 13th

    LOS ANGELES, CA / ACCESSWIRE / March 12 , 2019 / LD Micro, a company that puts on conferences for micro-cap and small-cap companies will be hosting 46 companies on March 12th (that's today) and 13th, starting ...

  • Imagine Owning Citius Pharmaceuticals (NASDAQ:CTXR) And Taking A 97% Loss Square On The Chin
    Simply Wall St.9 days ago

    Imagine Owning Citius Pharmaceuticals (NASDAQ:CTXR) And Taking A 97% Loss Square On The Chin

    This month, we saw the Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) up an impressive 45%. But that is meagre solace in the face of the shocking decline over three years. To wit,Read More...

  • ACCESSWIRE21 days ago

    Four Tech Stocks Looking To Test February Highs

    ParcelPal Technology Inc (PTNYF) (PKG), Citius Pharmaceuticals Inc(CTXR), VistaGen Therapeutics Inc (VTGN), and Frontier Communications Corporation (FTR) represent 4 tech stocks on the rise on Wednesday. The Company recognized an issue within the consumer marketplace: food delivery apps existed, but that was all we could order. Seizing the opportunity, ParcelPal created an on-demand marketplace where customers can purchase what they need and have their goods delivered within an hour.

  • PR Newswire2 months ago

    Citius Pharmaceuticals to Present at NobleCon15 Investor Conference

    CRANFORD, N.J. , Jan. 25, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, ...

  • PR Newswire2 months ago

    Citius Licenses Mino-Wrap From MD Anderson Cancer Center

    CRANFORD, N.J., Jan. 8, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today reported that a definitive license agreement has been reached with MD Anderson Cancer Center ("MDACC") to develop and commercialize a novel approach to reducing post-operative infections associated with surgical implants. There are approximately 100,000 patients in the U.S. undergoing breast reconstruction procedures following mastectomies.

  • PR Newswire2 months ago

    Citius Pharmaceuticals to Present at Biotech Showcase Investor Conference

    CRANFORD, N.J. , Jan. 4, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, ...

  • PR Newswire3 months ago

    Citius Pharmaceuticals Provides Updates on Mino-Lok® and CITI-002

    CRANFORD, N.J., Dec. 19, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided a status report today on Mino-Lok® and CITI-002. Mr. Myron Holubiak, CEO of Citius, said, "While there are significant challenges involved with studying an adjunctive therapy in patients with underlying serious life-threatening diseases, we are extremely pleased with the progress that has been made in the Phase-3 Mino-Lok® clinical trials.

  • PR Newswire3 months ago

    Citius Pharmaceuticals Presentation Now Available for On-Demand Viewing

    Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation CRANFORD, N.J. , Dec. 10, 2018 /PRNewswire/ -- Citius Pharmaceuticals ...

  • PR Newswire3 months ago

    Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th

    Company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , Dec. 4, 2018 /PRNewswire/ -- PR Newswire and BetterInvesting (NAIC) today announced the agenda for the ...

  • PR Newswire4 months ago

    Citius Pharmaceuticals to Present at the 11th Annual LD Micro Main Event

    CRANFORD, N.J. , Nov. 30, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug ...

  • PR Newswire4 months ago

    Citius Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com December 6

    Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com CRANFORD, N.J. , Nov. 29, 2018 /PRNewswire/ --  Citius ...

  • PR Newswire5 months ago

    Citius Pharmaceuticals to Present at Dawson James Securities 4th Annual Small Cap Growth Conference

    CRANFORD, N.J. , Oct. 25, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical ...

  • PR Newswire5 months ago

    Citius Reports On Activities During Infectious Disease Week 2018

    The Citius Scientific Advisory Board (SAB) meeting was held on October 4 to discuss the progress of the Mino-Lok® pivotal phase 3 trial and the design of the second trial (if needed). A meeting of many of the principal investigators of the Mino-Lok® pivotal phase 3 trial was also held on October 4, 2018.

  • PR Newswire6 months ago

    Citius Announces The Publication Of European Patent For Mino-Lok®

    CRANFORD, N.J., Sept. 27, 2018 /PRNewswire/ -- Citius Pharmaceuticals Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, received official notification from MD Anderson Cancer Center ("MDACC") that the European Patent Application (No. 16806326.1) for Mino-Lok with Enhanced Stability was published (September 12, 2018) under serial number 3370794. This patent which already received a Notice of Allowance from the US Patent and Trademark Office in July of 2018, and which patent was issued by the USPTO earlier this month, will provide and strengthen intellectual property protection for Mino-Lok through November of 2036.

  • PR Newswire6 months ago

    Citius Announces The Issuance Of The Patent On The Advanced Stability Of Mino-Lok® By USPTO

    CRANFORD, N.J., Sept. 25, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, received notice from MD Anderson Cancer Center ("MDACC") that the US Patent and Trademark Office ("USPTO") will issue United States Patent Number 10/086,114 entitled "Antimicrobial Solutions with Enhanced Stability" on October 2, 2018.

  • PR Newswire7 months ago

    Citius Pharmaceuticals Successfully Raises $10 Million

    CRANFORD, N.J., Aug. 15, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") ("CTXR"), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company completed the largest capital raise in its history of $10 million, and insiders were responsible for supporting 50% of the raise. Mr. Myron Holubiak, President and CEO of Citius Pharmaceuticals, invested $1 Million in the Company and Mr. Leonard Mazur, Executive Chairman of Citius Pharmaceuticals invested $4 Million to bring the deal into fruition.

  • PR Newswire7 months ago

    Citius Announces Closing of $10.0 Million Underwritten Offering Priced At-the-Market

    CRANFORD, N.J., Aug. 13, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the closing of the previously announced underwritten at-the-market offering of 7,843,138 shares of its common stock (Common Stock) (or Common Stock equivalent) and common warrants to purchase up to an aggregate of 7,843,138 shares of Common Stock (the Offering). Each share of Common Stock (or Common Stock equivalent) was sold together with a common warrant to purchase one share of Common Stock at a combined effective price of $1.275 per share and accompanying common warrant.

  • ACCESSWIRE7 months ago

    Pot Stocks & Biotech Stocks to Watch in 2018 & Beyond

    CORAL GABLES, FL / ACCESSWIRE / August 9, 2018 / Healthcare and biotechnology indexes are in the green this morning along with major markets pushing higher. The iShares Biotechnology Index (IBB) has risen an impressive 8.9% this year and has begun turning toward its 52-week high. GT Biopharma (GTBP) is a small cap biotech company with a vast pipeline of treatments.

  • PR Newswire7 months ago

    Citius Announces Pricing of $10.0 Million Underwritten Offering Priced At-the-Market

    CRANFORD, N.J., Aug. 9, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the pricing of an underwritten offering of 7,843,138 shares of its common stock (Common Stock) (or Common Stock equivalent) and common warrants to purchase up to an aggregate of 7,843,138 shares of Common Stock (the Offering), priced at-the-market. Each share of Common Stock (or Common Stock equivalent) is being sold together with a common warrant to purchase one share of Common Stock at a combined effective price of $1.275 per share and accompanying common warrant.

  • Zacks Small Cap Research8 months ago

    CTRX’s Ph3 Mino-Lok Fills Unmet Need for Catheter-Related Blood Infection Antibiotic

    OTC:ZENO NASDAQ:CTXR Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a specialty pharmaceutical company focused on the development and commercialization of proprietary formulations of already-approved drugs ...

  • PR Newswire8 months ago

    Citius Announces The Notice Of Allowance From The USPTO On The Advanced Stability Patent Application For Mino-Lok®

    CRANFORD, N.J., July 24, 2018 /PRNewswire/ -- Citius Pharmaceuticals Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, received notice from MD Anderson Cancer Center ("MDACC") that the US Patent and Trademark Office ("USPTO") has reviewed and examined the patent application US 2017/051373 A1 and that it is allowed for issuance as a patent.

  • PR Newswire8 months ago

    Citius Announces Key Addition to its Scientific Advisory Board

    CRANFORD, N.J., July 13, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company, announced that Dr. Lawrence Mermel has accepted a position on the Citius Scientific Advisory Board. Dr. Mermel is Professor of Medicine at the Warren Alpert Medical School of Brown University. Dr. Mermel joins Dr. Isaam Raad, the Chair of MD Anderson Cancer Center's Department of Infectious Diseases (also Chairman of the Citius Scientific Advisory Board), and Dr. Mark Rupp, Professor and Chief of the Division of Infectious Diseases at the University of Nebraska Medical Center.

  • PR Newswire8 months ago

    Citius Provides Clinical Update And Progress Of The Mino-Lok® Phase 3 Trial

    CRANFORD, N.J., July 9, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided a status report on the progress of the Mino-Lok Phase 3 clinical program. The Mino-Lok Phase 3 Trial is planned to enroll 700 patients in 50 participating institutions, all located in the U.S. There will be interim analyses at the 50% and 75% point of the trial as measured by the number of patients treated. Citius reports that as of this past week there are 12 active sites currently enrolling patients including such academic centers as MD Anderson Cancer Center, Henry Ford Health Center, Georgetown University Medical Center, University of Chicago, and others.

  • PR Newswire9 months ago

    Citius Announces United States Patent & Trademark Office Registered the Company's Mino-Lok® Trademark

    CRANFORD, N.J., June 19, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company, announced that Mino-Lok® is now a registered trademark with the U.S. Patent and Trademark Office.  Citius' Mino-Lok® product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). Citius' Mino-Lok® product is intended to salvage the CVC obviating the need to remove and replace the catheter.  This is a recognized unmet medical need. "We are working towards FDA approval and commercialization of Mino-Lok, We are currently conducting a Phase 3 clinical trial and are treating patients with Mino-Lok compared to standard antibiotic lock therapies," said Mr. Myron Holubiak, CEO of Citius.  "Hopefully, we will be able to complete our trial next year and begin the NDA review process.

  • PR Newswirelast year

    Citius Announces $2.0 Million Registered Direct Offering Priced At-the-Market

    CRANFORD, N.J., March 29, 2018 /PRNewswire/ -- Citius Pharmaceuticals Inc. (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 669,504 shares of its common stock, at a purchase price per share of $2.9850 for gross proceeds of approximately $2.0 million, in a registered direct offering priced at-the-market. Additionally, Citius has also agreed to issue to the investors unregistered warrants to purchase up to 669,504 shares of common stock. The warrants have an exercise price of $2.86 per share, will be immediately exercisable, and will expire five and a half years from the issue date.